AIM ImmunoTech furnished a press release detailing a Virtual Investor KOL segment spotlighting Ampligen's positive Named Patient Program data and Phase 2 interim progress in late-stage pancreatic cancer.
Key takeaways
Virtual Investor KOL Connect segment posted featuring Prof. Casper H.J. van Eijck and CEO Thomas K. Equels discussing Ampligen in pancreatic cancer.
Named Patient Program showed PFS of 12.6 months vs. 8.6 months historical controls and OS of 19.7 months vs. 12.5 months.
Stratified NPP data: Neutrophil/Lymphocyte <4.5 yielded PFS 17.7 months and OS 34.8 months vs. controls.
Ongoing Phase 2 DURIPANC study with Imfinzi reports positive interim progress; Mid-Year 2026 report and enrollment completion expected June 2026.
Ampligen progress published in peer-reviewed journals including 2024 paper on antitumor immunity.
Consistent Quality of Life improvements observed in NPP and DURIPANC.